CD34+ HSPCs

• Guaranteed post-thaw viability ≥ 90% as tested by NucleoCounter NC-200™
• Guaranteed post-thaw purity ≥ 90% as tested via flow cytometry

Mobilized CD34+ hematopoietic stem and progenitor cells (HSPCs) are isolated from mobilized leukopaks after single or dual mobilization agents are administered to healthy donors.

Contact us if you don’t see a specific product, size, or format, or would like to customize your request. 
^# Product will be discontinued and available only until inventory is depleted.

Your company or academic institution may be eligible for pricing discounts. Government labs located in the United States are also eligible for GSA MAS discounts. Request a quote to find out more.

REQUEST A QUOTE/ORDER

• Guaranteed post-thaw viability ≥ 80% as tested by NucleoCounter NC-200™
• Guaranteed post-thaw purity ≥ 90% as tested via flow cytometry

With more than 20 years of experience, our staff expertly performs bone marrow aspiration to maximize the collection of desired CD34+ HSPCs while ensuring donor safety and comfort.

Contact us if you don’t see a specific product, size, or format, or would like to customize your request. 
* Product is made to order.
^# Product will be discontinued and available only until inventory is depleted.

Your company or academic institution may be eligible for pricing discounts. Government labs located in the United States are also eligible for GSA MAS discounts. Request a quote to find out more.

REQUEST A QUOTE/ORDER

• Guaranteed post-thaw viability ≥ 80% as tested by NucleoCounter NC-200™
• Guaranteed post-thaw purity ≥ 90% as tested via flow cytometry

CD34+ hematopoietic stem and progenitor cells (HSPCs) are isolated from cord blood that is collected aseptically at the time of delivery from healthy pregnant women who have consented under an IRB-approved protocol. In general, CD34+ stem cells comprise between 0.2 and 0.5% of total nucleated cells in cord blood units. In addition to cryopreserved CD34+ HSPCs, our cord blood product portfolio also includes unprocessed cord blood.

Contact us if you don’t see a specific product, size, or format, or would like to customize your request. 

Your company or academic institution may be eligible for pricing discounts. Government labs located in the United States are also eligible for GSA MAS discounts. Request a quote to find out more.

REQUEST A QUOTE/ORDER

• Guaranteed post-thaw viability ≥ 90% as tested by NucleoCounter NC-200™
• Guaranteed post-thaw purity ≥ 90% as tested via flow cytometry

Contact us if you don’t see a specific product, size, or format, or would like to customize your request. 

Your company or academic institution may be eligible for pricing discounts. Government labs located in the United States are also eligible for GSA MAS discounts. Request a quote to find out more.

REQUEST A QUOTE/ORDER

What are Mobilized CD133+ HSPCs?

Mobilized CD133+ hematopoietic stem and progenitor cells (HSPCs) are isolated using positive immunomagnetic cell separation procedures from a mobilized leukapheresis collection. Cells expressing the CD133+ (AC133, Prominin-1) marker are generally known as primitive stem progenitor cells capable of a high level of proliferation and a wide range of differentiation. Transplantation of CD133+ cell lines have been shown to not only induce multi-lineage human hematopoiesis through the CD34+ lineage, but also induce regeneration of cell lines in vitro. 

CD34+ hematopoietic stem and progenitor cells (HSPCs) are multipotent and can give rise to all cell types in blood. CD34+ hematopoietic stem cells can be used for development of cell-based therapies, regenerative medicine studies, or with humanized mouse models for oncology research. CD34+ progenitor cells are also commonly used clinically as they have been shown to provide long-term durable donor-derived host lymphohematopoietic reconstitution.

Progenitor cells and CD34+ cells are often referred to interchangeably as stem cells. While this oversimplification is technically correct, there are many distinctions between the origins, functions, and uses of progenitor cells and CD34+ cells. Despite their many similarities, the most significant difference between the two cell types is that progenitor cells have a limited number of divisions, while CD34+ cells can divide and replicate indefinitely.

Potency
CD34+ stem cells give rise to all hematopoietic cells in the body, but progenitor cells are more targeted in their differentiation and can only produce a limited set of cells within a particular lineage (erythroid, myeloid, lymphoid). There are several stages of development for a progenitor cell to transform into a fully mature, differentiated cell.

Origin
CD34+ cells first originate as embryonic stem cells in the inner cell mass of blastocysts. These stem cells differentiate and give rise to every other cell type found in the human body.

Progenitor cells are descendants of CD34+ cells and are a stepping stone between the parent stem cell and the fully differentiated target cell.

Stem cell mobilization is the recruitment of CD34+ stem cells out of the bone marrow and into peripheral blood circulation following the administration of mobilizing agents.

Currently, mobilized peripheral blood is the predominant source of hematopoietic stem and progenitor cells for research support and clinical applications. It is used in the majority of allogeneic hematopoietic stem cell transplantation procedures¹. This is primarily due to its accessibility, relative ease of sourcing, and increased recallability potential for the donors leading to source material consistency. Transplant of mobilized CD34+ progenitor cells leads to rapid engraftment but can cause a higher risk of graft-versus-host disease (GVHD) when compared to cord blood- or bone marrow-derived CD34+ hematopoietic stem cells².

Collection by apheresis (leukapheresis) is a relatively low-risk procedure for the donor and is usually well tolerated. While the percentage of CD34+ stem cells in the mobilized leukopak can vary between 0.2% and 3% due to donor and dosing regimen differences, they are comparable to those derived from bone marrow aspiration. Collection volumes of mobilized leukopaks, usually 200 mLs to 400 mLs, are significantly greater than for either cord blood or bone marrow collections, normally leading to higher overall yields of CD34+ hematopoietic stem cells. 

For more information on mobilized CD34 stem cells, please check our comprehensive analysis examining how different mobilization agents, dosing schedules, and blood volume processed can impact CD34+ stem cell yields in mobilized leukopaks.

1. Auletta J.J., Kou J., Chen M., Shaw B.E. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR US summary slides, 2021.

2. Lipton J.M., Peripheral blood as a stem cell source for hematopoietic cell transplantation in children: is the effort in vein?. Pediatr Transplant. 2003;7 Suppl 3:65-70. doi:10.1034/j.1399-3046.7.s3.10.x

Fresh human bone marrow aspirate contains a large concentration of primitive CD34+ stem cells which make up about 1.5% of the total bone marrow cell population. Due to the self-renewal and multipotent nature of bone marrow stem cells, there is great interest in their potential applications for next generation drug discovery cell replacement studies, and self-repair. In addition, bone marrow-derived CD34+ progenitor cells are considered primitive and are associated with lower risk of graft-versus-host-disease (GVHD), but they are slow to engraft.

Bone marrow tissue produces and hosts the majority of HSPCs within the human body. As with cord blood-derived CD34+ hematopoietic stem cells, bone marrow-derived stem cell availability can be impacted by accessibility issues.

Collection volumes of cord blood are dependent on delivery with volume ranging around 60 mL to 80 mL and yielding approximately 1M – 3M CD34+ hematopoietic stem and progenitor cells per unit. Cord blood is relatively rich in CD34+ hematopoietic stem cells, simple to collect, and can allow for less stringent HLA matching criteria in clinical applications due to the presence of more primitive cell types compared to those found in bone marrow or peripheral blood. In addition, cord blood CD34+ hematopoietic stem cells exhibit a low risk for development of GVHD.

Due to sourcing issues, however, cord blood has limited availability compared to bone marrow or mobilized peripheral blood. Also, cord blood collected from a specific donor cannot be recalled, which can lead to inconsistencies in the CD34+ hematopoietic stem cell profile from collection-to-collection, making it more difficult for use for cell therapy development. While CD34+ hematopoietic stem cells derived from cord blood have greater plasticity than hematopoietic stem and progenitor cells derived from other sources, they also tend to have lower CD34+ stem cell total yields and thus may not be suitable for some applications.